Remetinostat - Medivir AB

Drug Profile

Remetinostat - Medivir AB

Alternative Names: SHAPE; SHP-141; SHP-141C; Suberohydroxamic acid phenyl ester (SHAPE)

Latest Information Update: 26 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Medivir AB; Shape Pharmaceuticals
  • Class Antineoplastics; Benzoic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous T cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 13 Oct 2017 Additional efficacy data from a phase II trial in Cutaneous T cell lymphoma released by Medivir
  • 12 Jun 2017 Stanford University plans a phase II trial for Basal cell cancer in USA (NCT03180528)
  • 07 Apr 2017 Additional efficacy data from a phase II trial in Cutaneous T cell lymphoma released by Medivir
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top